In This Article:
As global markets navigate choppy waters marked by inflation concerns and political uncertainties, investors are closely watching economic indicators and policy shifts that could influence future growth trajectories. In this environment, stocks with high insider ownership can offer a unique perspective on potential growth opportunities, as insiders often have a deep understanding of their company's long-term prospects.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Duc Giang Chemicals Group (HOSE:DGC) | 31.4% | 23.8% |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.2% |
| Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 25.4% |
| People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
| Medley (TSE:4480) | 34% | 27.2% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.3% |
| Plenti Group (ASX:PLT) | 12.8% | 120.1% |
| Fulin Precision (SZSE:300432) | 13.6% | 66.7% |
| Findi (ASX:FND) | 34.8% | 112.9% |
Below we spotlight a couple of our favorites from our exclusive screener.
Rusta
Simply Wall St Growth Rating: ★★★★★☆
Overview: Rusta AB (publ) is a retailer of home and leisure products operating in Sweden, Norway, Finland, and Germany, with a market cap of SEK11.40 billion.
Operations: The company's revenue segments are comprised of SEK6.49 billion from Sweden, SEK2.43 billion from Norway, and SEK2.39 billion from other markets.
Insider Ownership: 11.4%
Earnings Growth Forecast: 22.1% p.a.
Rusta demonstrates potential as a growth company with high insider ownership, evidenced by recent insider buying and no substantial selling. Despite slower revenue growth at 9.9% annually compared to the desired 20%, earnings are expected to grow significantly at 22.1% per year, outpacing the Swedish market's 14.3%. The stock trades well below its estimated fair value, while recent board changes may influence strategic direction positively.
-
Get an in-depth perspective on Rusta's performance by reading our analyst estimates report here.
-
Our valuation report here indicates Rusta may be undervalued.
Akeso
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company that focuses on researching, developing, manufacturing, and commercializing antibody drugs with a market cap of HK$51.12 billion.
Operations: The company generates revenue of CN¥1.87 billion from its activities in the research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 19%
Earnings Growth Forecast: 43.8% p.a.